Solara Active Pharma Sciences Limited has informed the exchange regarding submission of Machine Readable copy of Financial results for the quarter ended June 30, 2026

Q1FY27 results (unaudited): Standalone: Revenue 38.2bn +20% y-y (31.9bn) PAT 1.70bn +61% y-y (1.05bn) Consolidated: Revenue 38.2bn +20% y-y (31.9bn) PAT 1.63bn +55% y-y (1.05bn) FY26 results (audited): Standalone: Revenue 137.5bn +4% y-y (132.0bn) PAT -0.16bn (loss) vs prior year profit Consolidated: Revenue 137.5bn +4% y-y (132.0bn) PAT -0.07bn (loss) vs prior year profit Commentary: The Board approved preparation of results on a going concern basis despite accumulated losses, expecting renewal of working capital and improved operations.